Seminars in Oncology Nursing
Volume 24, Issue 1 , Pages 34-40 , February 2008

Advances in Radiation Therapy for Lung Cancer

  • Marilyn L. Haas

      Affiliations

    • Corresponding Author InformationAddress correspondence to Marilyn L. Haas, PhD, RN, CNS, ANP-C: Nurse Practitioner, Mountain Radiation Oncology, 90 Asheland Ave, Asheville, NC 28802

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Wingo P, Ries L, Giovino G, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section in lung cancer and tobacco smoking. J Natl Cancer Inst. 1999;91:675–690
  3. Hayes DN, Monti S, Parmigiani G, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol. 2006;24:5079–5090
  4. American Lung Association Lung Disease Data: 2006 Lung Cancer. Available at: http://www.lungusa.org/site/pp.asp?c=dvLUK9O0E&b=33347. pp 39–44 (accessed April 10, 2007).
  5. American Lung Association: Trends in lung cancer morbidity and mortality. September 2006. Available at: http://www.lungusa.org/atf/cf/%7B7A8D42C2-FCCA-4604-8ADE-7F5D5E762256%7D/TRENDLCREVISED0407.PDF (accessed April 10, 2007).
  6. Scott WJ, Howington J, Movas B American College of Chest Physicians. Treatment of stage II non-small cell lung cancer. Chest. 2003;123(suppl 1):188S–201S
  7. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer; first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991;83:417–423
  8. Perz C, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer. 1980;45:2744–2753
  9. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer. Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210–1215
  10. Sause W, Kolesar P, Taylor S, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest. 2000;117:358–364
  11. Curran WJ, Scott C, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol. 2003;22:621;(abstr 2499)
  12. Zatloukal P, Petrozelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer. 2004;46:87–98
  13. Fletcher G. Clinical dose response curves of human malignant epithelial tumours. Br J Radiol. 1973;46:1–12
  14. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomized multicenter trial. Lancet. 1997;350:161–167
  15. Mehta M, Tannehill S, Adak S, et al. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593. J Clin Oncol. 1998;16:3518–3523
  16. Saunders MI, Rojas A, Lyn BE, et al. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. Clin Oncol. 2002;14:352–360
  17. National Comprehensive Cancer Network. NCCN Practice Guideline in Oncology: Non-small cell lung cancer, v. 1.2007. Available at: http://www.nccn.org/professionals/physician_gls/default.asp. (accessed April 1, 2007).
  18. Kerstine K, Trapp J, Croft D, et al. Comparison of positron emission tomography (PET) and computed tomography (CT) to identify N2 and N3 disease in non small cell lung cancer (NSCLC). J Clin Oncol. 1998;17:458;(abstr)
  19. Francis IR, Brown RK, Avram AM. The clinical role of CT/PET in oncology: an update. Cancer Imag. 2005;5:S68–S75
  20. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001;51:880–914
  21. Michalski J, Purdy J, Gaspar L, et al. Image-Guided Radiation Therapy Committee. Int J Radiat Oncol Biol Phys. 2001;51:60–65
  22. Onimaru R, Shirato H, Shimizu S, et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2003;56:126–135
  23. Mackie T, Kapatoes J, Ruchala K, et al. image guidance for precise conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:89–105
  24. Decker TW, Cline-Elsen J, Gallagher M. Relaxation therapy as an adjunct in radiation oncology. Clin Psychol. 1992;48:388–393
  25. Radiation Therapy Oncology Group(RTOG). http://www.rtog.org/members/protocols/0236/0236broadcast.html (accessed April 1, 2007).
  26. Manon R, Mehta M. Strategies for enhanced radiation delivery in patients with lung cancer. Expert Opin Drug Deliv. 2005;1:103–113

PII: S0749-2081(07)00139-8

doi: 10.1016/j.soncn.2007.11.010

Seminars in Oncology Nursing
Volume 24, Issue 1 , Pages 34-40 , February 2008

Article Tools

* Image Usage & Resolution